{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:38:29Z","timestamp":1789015109420,"version":"build-2803163510"},"reference-count":37,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81920108006"],"award-info":[{"award-number":["81920108006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270218"],"award-info":[{"award-number":["82270218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20291"],"award-info":[{"award-number":["U22A20291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS | Chinese Academy of Medical Sciences Initiative for Innovative Medicine","award":["2022-I2M-1-022"],"award-info":[{"award-number":["2022-I2M-1-022"]}]},{"name":"CAMS | Chinese Academy of Medical Sciences Initiative for Innovative Medicine","award":["2021-I2M-1-041"],"award-info":[{"award-number":["2021-I2M-1-041"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,6]]},"abstract":"<jats:p>Attaining undetectable minimal residual disease (MRD) is the current therapeutic goal for multiple myeloma. But there is a current lack of data regarding the clinical benefit of autologous stem cell transplantation (ASCT) for patients with myeloma achieving early MRD-negative status after induction treatment, in addition to the interaction of longitudinal MRD status with ASCT. The current study included 407 patients with transplant-eligible multiple myeloma with available MRD status from the National Longitudinal Cohort of Hematological Diseases in China (NCT04645199), of whom 147 (34.4%) achieved early undetectable MRD and 182 (44.7%) received ASCT. Early MRD-negative status was associated with a lower risk of disease progression [HR = 0.447; 95% confidence interval (CI), 0.333\u20130.600; P &amp;lt; 0.001] and death (HR = 0.473; 95% CI, 0.320\u20130.700; P &amp;lt; 0.001). Of note, patients who achieved undetectable MRD early still benefitted from ASCT, with a remarkable improvement in the median MRD-negative duration (33.5\u201358.0 months, P &amp;lt; 0.001), progression-free survival (PFS; 46.0\u201388.3 months, P &amp;lt; 0.001), and overall survival (OS; 76.4 months to not reached, P = 0.003). These clinical benefits were more pronounced in patients with aggressive features (high-risk cytogenetic abnormalities or high tumor burden) compared with standard-risk patients. Similar results were observed in patients with detectable MRD after induction treatment. In addition, we identified four MRD-status transformation patterns following ASCT, which were strongly correlated with diverse survival outcomes (P &amp;lt; 0.001). Our study revealed the enhanced clinical significance of ASCT in patients with transplant-eligible myeloma, regardless of early MRD status, particularly for high-risk patients. Subsequent prospective trials are essential to validate these observations.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Achieving and maintaining undetectable MRD is the current treatment goal for multiple myeloma. Our results emphasized the remarkable clinical benefit of ASCT on MRD-negative duration, PFS, and OS in patients with multiple myeloma regardless of early MRD status. These favorable impacts were more evident in patients with aggressive features. Importantly, dynamic MRD monitoring among ASCT could facilitate personalized stratification of therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0185","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T09:17:03Z","timestamp":1692091023000},"page":"1770-1780","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-2612","authenticated-orcid":true,"given":"Jiahui","family":"Liu","sequence":"first","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."},{"name":"3Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6813-7810","authenticated-orcid":true,"given":"Wenqiang","family":"Yan","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2011-8409","authenticated-orcid":true,"given":"Huishou","family":"Fan","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-2072","authenticated-orcid":true,"given":"Jingyu","family":"Xu","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2396-8892","authenticated-orcid":true,"given":"Lingna","family":"Li","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-6602","authenticated-orcid":true,"given":"Chenxing","family":"Du","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-9604","authenticated-orcid":true,"given":"Xuehan","family":"Mao","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-2984","authenticated-orcid":true,"given":"Yuting","family":"Yan","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6167-3319","authenticated-orcid":true,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6982-8258","authenticated-orcid":true,"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6564-8552","authenticated-orcid":true,"given":"Shuhui","family":"Deng","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-812X","authenticated-orcid":true,"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":true,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"4LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-0644","authenticated-orcid":true,"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-4913","authenticated-orcid":true,"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-4614","authenticated-orcid":true,"given":"Gang","family":"An","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China."},{"name":"2Tianjin Institutes of Health Science, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"2023090614050503200_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"2023090614050503200_bib2","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"2023090614050503200_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2023090614050503200_bib4","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.22.00622","article-title":"Modern myeloma therapy + sustained minimal residual disease-negative = (Functional) cure!","volume":"40","author":"Landgren","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023090614050503200_bib5","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023090614050503200_bib6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023090614050503200_bib7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"2023090614050503200_bib8","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"2023090614050503200_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2021-145533","article-title":"Biologic basis of the impact of autologous hematopoietic cell transplantation in multiple myeloma treated with quadruplet therapy","volume":"138","author":"Bal","year":"2021","journal-title":"Blood"},{"key":"2023090614050503200_bib10","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"2023090614050503200_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"2023090614050503200_bib12","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023090614050503200_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamaoncol.2016.3112","article-title":"Minimal residual disease as a potential surrogate end point-lingering questions","volume":"3","author":"Gormley","year":"2017","journal-title":"JAMA Oncol"},{"key":"2023090614050503200_bib14","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"2023090614050503200_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J"},{"key":"2023090614050503200_bib16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023090614050503200_bib17","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023090614050503200_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"key":"2023090614050503200_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023090614050503200_bib20","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/bloodadvances.2019000432","article-title":"The impact of response kinetics for multiple myeloma in the era of novel agents","volume":"3","author":"Yan","year":"2019","journal-title":"Blood Adv"},{"key":"2023090614050503200_bib21","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/cncr.34641","article-title":"The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: the faster, the worse","volume":"129","author":"Wang","year":"2023","journal-title":"Cancer"},{"key":"2023090614050503200_bib22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"2023090614050503200_bib23","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.3390\/cancers13194867","article-title":"Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers"},{"key":"2023090614050503200_bib24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1172\/JCI30414","article-title":"Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells","volume":"117","author":"Wrzesinski","year":"2007","journal-title":"J Clin Invest"},{"key":"2023090614050503200_bib25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2021-149112","article-title":"Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)","volume":"138","author":"Maura","year":"2021","journal-title":"Blood"},{"key":"2023090614050503200_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2021-154506","article-title":"Normalization of the immune microenvironment during lenalidomide maintenance is associated with sustained MRD negativity in patients with multiple myeloma","volume":"138","author":"Coffey","year":"2021","journal-title":"Blood"},{"key":"2023090614050503200_bib27","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"},{"key":"2023090614050503200_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J"},{"key":"2023090614050503200_bib29","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2022017094","article-title":"High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"key":"2023090614050503200_bib30","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"key":"2023090614050503200_bib31","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"2023090614050503200_bib32","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"key":"2023090614050503200_bib33","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume":"141","author":"Diamond","year":"2023","journal-title":"Blood"},{"key":"2023090614050503200_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"key":"2023090614050503200_bib35","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023090614050503200_bib36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/bloodadvances.2018022806","article-title":"Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma","volume":"3","author":"Tandon","year":"2019","journal-title":"Blood Adv"},{"key":"2023090614050503200_bib37","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New developments in diagnosis, prognosis, and assessment of response in multiple myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0185\/3356145\/crc-23-0185.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1770\/3362760\/crc-23-0185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1770\/3362760\/crc-23-0185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:05:56Z","timestamp":1693994756000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/9\/1770\/728914\/Clinical-Benefit-of-Autologous-Stem-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,6]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0185","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.23957772.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957778.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6790341.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957775.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957775","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957787","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6790341","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957790","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957778","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957769","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957781.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957781","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957769.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957793","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957796.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957787.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957784.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957790.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6790341.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957796","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957784","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957793.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957772","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24092425.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957769.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957769","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092392","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957784.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957781.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092401","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957787.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092413","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092395.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092425","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092422.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092398.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092392.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092428.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957796","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957772","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957784","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092401.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092410.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092395","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092413.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092416","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092428","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092404","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957775","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092404.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092407.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092431.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957787","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957775.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092416.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092419.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092431","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092398","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092386","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957793.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957796.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092407","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957790","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957790.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092419","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957778","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092386.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092389.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092389","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092410","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24092422","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957781","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957772.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957778.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23957793","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}